Treatment with DNA methyltransferase inhibitor can activate Cav‐1 through demethylation of CpGi shores as therapeutic potentials for lung diseases, although there still are a large number of challenges to be overcome to meet criteria of disease‐specific biomarkers and targets to dynamically monitor disease severity, duration, stage, and response to therapy.96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111. Here, CAV1 is linked to lung disorder.